

Article

Chemical Constituents of the Marine-Derived Fungus *Aspergillus* sp. SCS-KFD66

Chang-Liang An ^{1,2,†}, Fan-Dong Kong ^{1,†}, Qing-Yun Ma ¹, Qing-Yi Xie ¹, Jing-Zhe Yuan ¹, Li-Man Zhou ¹, Hao-Fu Dai ¹, Zhi-Fang Yu ^{2,*} and You-Xing Zhao ^{1,*}

¹ Hainan Key Laboratory for Research and Development of Natural Product from Li Folk Medicine, Institute of Tropical Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences, Haikou 571101, China; annncl@163.com (C.-L.A.); kongfandong@itbb.org.cn (F.-D.K.); maqingyun@itbb.org.cn (Q.-Y.M.); xieqingyi@itbb.org.cn (Q.-Y.X.); jingzhe1989@yahoo.com (J.-Z.Y.); zhouliman88@126.com (L.-M.Z.); daihaofu@itbb.org.cn (H.-F.D.)

² College of Food Science and Technology, Nanjing Agricultural University, Nanjing 210095, China

* Correspondence: yuzhifang@njau.edu.cn (Z.-F.Y.); zhaoyouxing@itbb.org.cn (Y.-X.Z.); Tel.: +86-139-5169-2350 (Z.-F.Y.); +86-898-6698-9095 (Y.-X.Z.)

† These authors contributed equally to this paper.

Received: 5 November 2018; Accepted: 21 November 2018; Published: 26 November 2018



Abstract: Five new compounds named asperpenes A-C (1–3), 12,13-dedihydroversiol (4), and methyl 6-oxo-3,6-dihydro-2H-pyran-4-carboxylate (5), along with 10 known compounds (6–15), were isolated from the fermentation broth of *Aspergillus* sp. SCS-KFD66 associated with a bivalve mollusk, *Sanguinolaria chinensis*, collected from Haikou Bay, China. The structures of the compounds, including the absolute configurations of their stereogenic carbons, were unambiguously determined by spectroscopic data, single-crystal X-ray diffraction analysis, and electronic circular dichroism (ECD) spectral analysis, along with quantum ECD calculations. The growth inhibitory activity of the compounds against four pathogenic bacterial (*Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 6538, *Listeria monocytogenes* ATCC 1911, and *Bacillus subtilis* ATCC 6633), their enzyme inhibitory activities against acetylcholinesterase and α -glucosidase, and their DPPH radical scavenging activity were evaluated.

Keywords: marine-derived fungus; *Aspergillus* sp.; secondary metabolites; antibacterial activity

1. Introduction

In the past few decades, natural products have occupied a very important position in modern drug research and development, providing more efficient means for human health care, nutrition, medical care, and other aspects [1]. From 1940 to 2014, 175 new anticancer drugs were approved worldwide, 75% of which came from natural products or their derivatives [2]. Therefore, the study of natural products is of great significance for drug development. Because of the special environmental conditions, marine fungi have been proven to be a rich source of various types of compounds with complex structures and remarkable activities, thereby attracting the attention of for which many natural product chemists turned their attention to them [3,4].

Our previous research on secondary metabolites from marine animal-derived fungi have led to the isolation and identification of a series of structurally new and biologically active natural products, including new quorum-sensing inhibitors from *Penicillium* sp. SCS-KFD08, chlorinated meroterpenoids with anti-H1N1 activity from *Penicillium* sp. SCS-KFD09, and helvolic acid derivatives with potent antibacterial activity from *Aspergillus fumigatus* HNMF0047 [5–9]. In the course of our ongoing research, *Aspergillus* sp. SCS-KFD66 was isolated and

identified from a bivalve mollusk, *Sanguinolaria chinensis*, from Haikou Bay, Hainan province, in China. The chemical investigation on the EtOAc extract of the fungal fermentation broth led to the isolation and purification of five new compounds, named asperpenes A-C (**1-3**), 12,13-dedihydroversiol (**4**), and methyl 6-oxo-3, 6-dihydro-2*H*-pyran-4-carboxylate (**5**), as well as 10 known compounds, i.e., versiol (**6**) [10], (*E*)-4-oxonon-2-enoic acid (**7**) [11], ergosta-5, 7,22-triene-3 β -ol (**8**) [12], β -sitosterol (**9**) [13], (22*E*)-5 α ,8 α -epidioxyergosta-6,22-dien-3 β -ol (**10**) [14], 15 α -hydroxy-(22*E*,24*R*)-ergosta-3,5,8(14),22-tetraen-7-one (**11**) [15], volemolide (**12**) [16], oxaline (**13**) [17], fumitremorgin B (**14**) [18], and helvolic acid (**15**) [19] (Figure 1). Herein, the structure and bioactivities of these compounds are reported.




Figure 1. Structures of compounds 1–15.

2. Results and Discussion

Compound **1** was obtained as a colorless crystal, and its molecular formula $C_{15}H_{20}O_4$ was established from the HRESIMS m/z 263.1283 $[M - H]^-$. The IR absorptions at 3422, 1695, and 1622 cm^{-1} revealed the presence of a hydroxyl and a conjugated carboxylic group, respectively, which was further confirmed by a characteristic UV λ_{max} at 221 nm. The 1H and ^{13}C NMR spectra (Supplementary Materials, Figures S1 and S2) in combination with the HSQC spectra (Supplementary Materials, Figure S4) revealed the presence of two methyls, four sp^3 methylenes, three sp^3 methines, two sp^3 non-protonated carbons, one tri-substituted double bond, and two carboxylic groups. These data were closely related to those of russujaponol H [20], suggesting that **1** was also an illudoid sesquiterpene. The COSY correlations (Supplementary Materials, Figure S5) revealed the connectivities from in CH-1–CH-2–CH-9–CH₂-10, CH-8–CH-9, and CH₂-4–CH₂-5–CH-6. These structure fragments were assembled into a whole structure on the basis of the HMBC correlations (Supplementary Materials, Figure S6) from H₃-12 (δ_H 1.25) to C-2 (δ_C 47.0), C-3 (δ_C 49.2), C-4 (δ_C 26.6), and C-6 (δ_C 37.2), from H₃-15 (δ_H 1.18) to C-1 (δ_C 39.8), C-10 (δ_C 44.5), C-11 (δ_C 39.0), and C-14 (δ_C 182.4), from H-6 (δ_H 2.54) to C-5 (δ_C 30.7) and C-7 (δ_C 133.9), and from H-8 (δ_H 6.82) to C-13 (δ_C 170.3) (Figure 2). ROESY correlations from H-6/H-1 β (δ_H 0.96)/H₃-15 and H-8 (δ_H 6.82)/H-10 β (δ_H 1.59) (Figure 3) suggested that H-6 and H₃-15 were on the same face of the ring system, and H-2 (δ_H 1.98) and H-9 (δ_H 2.92) were

on the opposite face of the molecule (Figure 3). To support the above deduction and determine the absolute configuration of **1**, a single-crystal X-ray diffraction pattern was obtained using the anomalous scattering of Cu K α radiation (Figure 4), allowing an explicit assignment of the absolute structure as 2*S*, 3*R*, 6*R*, 9*S*, and 11*R*. This was further corroborated by electronic circular dichroism (ECD) quantum chemical calculations in Gaussian 03 [7]. The experimental and calculated ECD spectra for (2*S*, 3*R*, 6*R*, 9*S*, 11*R*)-**1** showed good agreement (Figure 5). Thus, **1** was elucidated and named asperpene A.




Figure 2. Key COSY (—) and HMBC (---) correlations of 1–5.




Figure 3. Key ROESY correlations of 1–4.




Figure 4. ORTEP diagrams of **1** and **6**.




Figure 5. Comparison of measured and calculated ECD spectra for **1** and **4** and ECD exciton chirality model for **4**.

Compound **2** was obtained as a colorless powder, whose molecular formula was established as $C_{15}H_{22}O_3$ by HRESIMS m/z 273.1455 $[M + Na]^+$. Comparison of the 1H and ^{13}C NMR data (Supplementary Materials, Figures S9 and S10) of **2** with those of **1** revealed the presence of a hydroxymethyl group ($\delta_{C/H}$ 72.1/3.3, C-14) and a carboxylic group in **2** instead of two carboxyl groups as in **1**. The above data, together with HMBC correlations from H₃-15 (δ_H 0.96) to the hydroxymethyl carbon (δ_C 72.1), indicated that the carboxylic group in **1** was replaced by a hydroxymethyl in **2**. In the ROESY spectrum (Figure 3), correlations from H₂-14 (δ_H 3.31, 3.33)/H-1 α (δ_H 1.56), H-6 (δ_H 1.91)/H-1 β (δ_H 0.85), and H-9 (δ_H 2.88)/H-4 α (δ_H 1.86) suggested that **2** shared the same configuration at the stereogenic C-2, C-3, C-6, C-9, and C-11. Thus, the structure of **2** was established and named as asperpene B.

Compound **3** possessed the same molecular formula as **2**, as determined by HRESIMS data. The 1H and ^{13}C NMR data of **3** (Supplementary Materials, Figures S17 and S18) were also quite similar to those of **2**. However, in the HMBC spectrum of **3** (Figure 2), correlations from H₃-15 (δ_H 1.26) to the carbonyl (δ_C 201.5) and from H₂-13 (δ_H 4.01, 4.03) to C-7 (δ_C 139.5) and C-8 (δ_C 125.5) suggested the positions of the carboxylic acid and the hydroxymethyl groups at C-11 and C-7, respectively, which is resulted different from those of **2**. ROESY correlations (Figure 3) of H-10 β (δ_H 1.57)/H-8 (δ_H 5.49) and H₃-15/H-1 β (δ_H 1.09)/H-6 (δ_H 1.99) suggested that **3** had the same configurations of its stereogenic carbons as **2**.

Compound **4** was obtained as a yellow oil, and its molecular formula was determined as $C_{16}H_{20}O_3$ on the basis of the HRESIMS data, implying seven degrees of unsaturation. The 1H and ^{13}C NMR data (Supplementary Materials, Figures S25 and S26) of **4** indicated the presence of three methyls, one methylene, eight methines (including five olefinic and one oxygenated), and four non-protonated carbons (including one ketone carbonyl, one olefinic, and one oxygenated sp^3). These data were quite similar to those of versiol (**6**) [10], suggesting that they were structurally related, and the only difference was that one disubstituted double bond in **4** was saturated to two vicinal methylenes in **6**, as supported

by HMBC correlations from H-13 (δ_{H} 7.22) to C-8 (δ_{C} 85.9) and from H-12 (δ_{H} 5.46) to C-11 (δ_{C} 198.8). ROESY correlation between H-2 β (δ_{H} 1.19) and H-10 (δ_{H} 2.69) suggested their cofacial relationship, while the absence of ROESY correlations from H₃-14 (δ_{H} 1.46) and H₃-15 (δ_{H} 1.17) to H-10 suggested that H₃-14 and H₃-15 were on the opposite face with respect to H-10. Considering that versiol (**6**) and **4** were biosynthetically related and a relatively large amount of versiol (**6**) was isolated, we crystallized versiol (**6**) successfully and subjected it to a single-crystal X-ray diffraction experiment (Figure 4), finally allowing an explicit assignment of the absolute structure of versiol (**6**) as 1*S*, 3*S*, 8*S*, 9*R*, and 10*S*. The absolute configurations of the stereogenic carbons of **4** were also suggested to be 1*S*, 3*S*, 8*S*, 9*R*, and 10*S* on the basis of a biosynthetic consideration. The experimental ECD spectrum (Figure 5) of **4** showed characteristic exciton CD absorption bands at 261 (-0.31) and 230 (+0.14) nm due to the a negative couplet of the α,β -unsaturated carbonyl and the conjugated double-bond moieties, which further confirmed the absolute configuration assignment. Moreover, the experimental and calculated ECD spectra for **4** also matched well (Figure 5).

Compound **5** was isolated as a colorless oil, whose molecular formula was established as C₇H₈O₄ by HRESIMS m/z 179.0316 [M + Na]⁺. The ¹H, ¹³C, and HSQC NMR spectra (Supplementary Materials, Figures S33, S34, and S36) of **5** showed signals for two ester carbonyls (δ_{C} 165.0, 163.6), one tri-substituted double bond ($\delta_{\text{C}/\text{H}}$ 126.1/6.77, 145.3), two sp³ methylenes, one of which is oxogenated ($\delta_{\text{C}/\text{H}}$ 66.7/4.46), and one methoxyl group ($\delta_{\text{C}/\text{H}}$ 53.1/3.87). COSY correlations (Supplementary Materials, Figure S37) of H₂-2 (δ_{H} 4.46)/H₂-3 (δ_{H} 2.71) and HMBC correlations (Supplementary Materials, Figure S38) from H₂-2 (δ_{H} 4.46) and H-5 (δ_{H} 6.77) to C-6 (δ_{C} 163.6) and C-4 (δ_{C} 145.3) and from H₂-3 and H₃-8 (δ_{H} 3.87) to C-7 (δ_{C} 165.0) led to the determination of the full structure of **5**, as shown in Figure 1.

Compounds **1–15** were tested for their antibacterial activity against *Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 6538, *Listeria monocytogenes* ATCC 1911, and *Bacillus subtilis* ATCC 6633 by the 96-well microtiter plates method [21]. The results (Table 1) revealed that **7**, **8**, **12**, and **13** showed inhibitory activities against *B. subtilis* ATCC 6633, with MIC values of 4, 128, 128, and 128 $\mu\text{g}/\text{mL}$, respectively, whereas **7**, **8**, **14**, and **15** showed inhibitory activity against *S. aureus* ATCC 6538, with MIC values of 16, 128, 128 and 2 $\mu\text{g}/\text{mL}$, respectively; **15** also had inhibitory activity against *L. monocytogenes* ATCC 1911, with MIC value of 128 $\mu\text{g}/\text{mL}$. None of these compounds showed inhibitory activity against *E. coli* ATCC 25922.

Table 1. Antibacterial activities of compounds **7**, **8**, and **12–15**.

Compound	MIC ($\mu\text{g}/\text{mL}$)		
	<i>Staphylococcus aureus</i> ATCC 6538	<i>Listeria monocytogenes</i> ATCC 1911	<i>Bacillus subtilis</i> ATCC 6633
7	16	>128	4
8	128	>128	128
12	>128	>128	128
13	>128	>128	128
14	128	>128	>128
15	2	128	>128
Ampicillin ^a	<1	<1	<1

^a Positive control.

Additionally, the DPPH radical scavenging activity and the acetylcholinesterase and α -glucosidase inhibitory activities of all the isolated compounds were evaluated by the DPPH method [22], Ellman colorimetric method [23], and PNPG method [24], respectively. None of these compounds showed inhibitory activities against α -glucosidase and acetylcholinesterase. However, **1**, **3**, **4**, **8**, **11**, and **15** showed weak DPPH radical scavenging activity, with IC₅₀ values of 1.8, 0.6, 1.1, 0.6, 1.2, and 0.7 mM (ascorbic acid as positive control, IC₅₀ 0.04 mM).

3. Experimental Section

3.1. General Experimental Procedure

Optical rotations were measured with a JASCO P-1020 digital polarimeter. The IR spectra were obtained on with a Nicolet Nexus 470 spectrophotometer as KBr discs. The UV spectra were obtained from with a Beckman DU 640 spectrophotometer. ECD data were measured collected on using a JASCO J-715 spectropolarimeter. The NMR spectra were recorded on a Bruker AV-500 spectrometer with TMS as an internal standard. ESIMS, HRESIMS, and HREIMS data were acquired on a Micromass Autospec-Ultima-TOF, API QSTAR Pulsar 1, or Waters Autospec Premier spectrometer. The sea salt was produced by evaporation of seawater collected in Laizhou Bay, Weifang, China (Weifang HaiHua Yu Feng Chemical Factory). Semi-preparative HPLC separation was used octadecyl silane (ODS) columns (YMC-pack ODS-A, 10 × 250 mm, 5 μm, 4 mL/min) and Ph column (YMC-pack Ph, 10 × 250 mm, 5 μm, 4 mL/min) for separation. Thin-layer chromatography (TLC) and column chromatography (CC) were carried out on precoated silica gel GF₂₅₄ (10–40 μm, Qingdao Marine Chemical Inc., Qingdao, China) and silica gel (200–300 mesh, Qingdao Marine Chemical Inc., Qingdao, China), respectively.

3.2. Fungal Material and Fermentation

The strain SCS-KFD66 was isolated from a bivalve mollusk, *Sanguinolaria chinensis*, collected from Haikou Bay, Hainan province, in China. After grinding, the sample (1 g) was diluted to 10⁻² g/mL with sterile H₂O, 100 μL of which was spread on a PDA (200 g potato, 20 g glucose, 20 g agar per liter of sea water collected in Haikou Bay, China) plate containing chloramphenicol (100 μg/mL) as a bacterial inhibitor. Fungal identification was carried out by its examining the morphological characteristics and 18S rRNA gene sequences (GenBank accession No. MK085984, Supporting Information) with of the single colonies. A reference culture of *Aspergillus* sp. SCS-KFD66 is deposited in our laboratory and which maintained at -80 °C. The isolate was cultured on slants of PDA medium at 28 °C for 5 days and then transferred to two hundred 1 L Erlenmeyer flasks containing solid rice medium (80 g rice, 3.96 g sea salt, 120 mL tap water, pH 7.0), used for fermentation. The flasks were incubated under static conditions at room temperature for 30 days.

3.3. Extraction and Isolation

The fermented cultures were extracted with three-fold volumes (3 × 300 mL) of EtOAc, then filtered through a cheesecloth to separate the rice from the mixture. After repeating the procedure three times, the EtOAc extracts were evaporated under a reduced pressure to produce 409.6 g of a crude extract. The extract was fractionated by a silica gel VLC column using different solvents of increasing polarity, from petroleum ether to EtOAc, to yield seven fractions (Frs. 1–7). Fr. 3 (5.3 g) was further purified by HPLC using an octadecyl silane (ODS) silica gel column and eluted with in a MeOH/H₂O (1:5, 2:3, 3:2, 4:1, 1:0) gradient to afford **8** (3.5 mg), **9** (14.0 mg), and three subfractions (Sfrs. 3-1–Fr. 3-3). Sfr. 3-2 (289.7 mg) was subjected to VLC on silica gel and eluted with an EtOAc/petroleum ether stepwise gradient (from 1:10 to 2:1) to afford **4** (3.6 mg). Fr. 4 (8.0 g) was separated into seven subfractions (Sfrs. 4-1–Fr-4-7) by HPLC using an ODS silica gel column with a gradient elution of MeOH/H₂O (1:5, 2:3, 3:2, 4:1, 1:0). Sfr. 4-1 (16.5 mg) was purified by a semipreparative HPLC (YMC-pack ODS-A, 5 μm; 10 × 250 mm; 35% MeCN/H₂O; containing 0.1% TFA; 4 mL/min) to afford **7** (*t*_R 18.4 min; 1.7 mg). Fr. 5 (3.7 g) was chromatographed on an ODS silica gel column with a gradient elution of MeOH/H₂O (1:5, 2:3, 3:2, 4:1, 1:0) to yield **14** (3.0 mg), **15** (4.1 mg), **10** (5.2 mg), and four subfractions (Sfrs. 5-1–Fr. 5-4). Sfr. 5-4 (13.3 mg) was purified by a semipreparative HPLC (YMC-pack ODS-A, 5 μm; 10 × 250 mm; 40% MeCN/H₂O; containing 0.1% TFA; 4 mL/min) to afford **6** (*t*_R 9.8 min; 6.0 mg). Fr. 6 (4.0 g) was fractionated on an ODS silica gel column with a gradient elution of MeOH/H₂O (1:5, 2:3, 3:2, 4:1, 1:0) to yield six subfractions (Sfrs. 6-1–Fr. 6-6). Sfr. 6-4 (69.9 mg) was subjected to semipreparative HPLC (YMC-pack Ph, 5 μm; 10 × 250 mm; 30% MeCN/H₂O; containing

0.1% TFA; 4 mL/min) to afford **1** (t_R 15.6 min; 24.5 mg), **2** (t_R 18.4 min; 2.5 mg), and **3** (t_R 21.5 min; 3.7 mg). Purification of Fr. 7 (28.3 g) by a silica gel VLC column with a stepwise gradient with of MeOH/CHCl₃ (from 10:90 to 100:0) gave **13** (78.5 mg) and eight fractions (Sfrs. 7-1–Fr. 7-8). Sfr. 7-1 (119.2 mg) was applied to ODS silica gel with a gradient elution of MeOH/H₂O (1:5, 2:3, 3:2, 4:1, 1:0) to yield **12** (2.0 mg). Sfr. 7-2 (199.4 mg) was purified by ODS silica gel column with a gradient elution with of MeOH/H₂O (1:5, 2:3, 3:2, 4:1, 1:0) to give **11** (3.0 mg). Sfr. 7-4 (184.9 mg) was purified by Sephadex LH-20 chromatography and eluted with MeOH to give three subfractions (Sfrs. 7-4-1–Fr. 7-4-3). Sfr. 7-4-1 (149.6 mg) was finally purified by semipreparative HPLC (YMC-pack ODS-A, 5 μ m; 10 \times 250 mm; 40% MeOH/H₂O; 4 mL/min) to obtain **5** (t_R 4.4 min; 9.3 mg).

Asperpene A (**1**): Colorless crystal; mp 194–195 °C; $[\alpha]_D^{25}$ +8 (c 0.1, MeOH); UV (MeOH) λ_{max} (log ϵ): 203 (3.54) nm; ECD (MeOH) λ_{max} 221 (+0.34) nm; IR (KBr) ν_{max} (cm⁻¹): 3422, 2930, 2851, 1695, 1626, 1453, 1390, 1254, 1121. ¹H NMR data, Table 2; ¹³C NMR data, Table 3; HRESIMS m/z 263.1283 [M – H]⁻ (calcd for C₁₅H₁₉O₄, 263.1289).

Table 2. ¹H NMR data (500 MHz, δ in ppm, J in Hz) of **1**–**5**.

Position	1 ^a	2 ^b	3 ^b	4 ^b	5 ^b
1	2.11, dd (12.9, 7.1) 0.96, dd (12.9, 12.1)	1.56, dd (12.8, 7.5) 0.85, dd (12.8, 12.8)	2.12, dd (12.8, 7.3) 1.09, dd (12.7, 12.7)	3.95, m	
2	1.98, m	2.60, m	2.24, m	1.96, m 1.19, ddd (12.6, 12.6, 1.7)	4.46, t (6.2)
3				2.64, m	2.71, td (6.2, 1.7)
4	2.49, m 1.42, m	1.86, m 1.48, m	1.96, m 1.48, m	5.81, d (2.0)	
5	1.90, m 1.46, m	2.51, m 1.48, m	2.41, m 1.48, m		6.77, t (1.7)
6	2.54, m	1.91, overlap	1.99, m	6.31, d (9.6) 5.48, d (9.6)	
7					
8	6.82, d (2.3)	6.97, d (2.2)	5.49, d (2.0)		3.87, s
9	2.92, m	2.88, m	2.81, m		
10	2.66, dd (13.6, 8.9) 1.59, dd (13.6, 1.9)	1.95, dd (13.7, 8.9) 1.50, overlap	2.59, dd (13.5, 8.2) 1.57, dd (13.5, 1.6)	2.69, m	
12	1.25, s	1.24, s		1.22, s	5.46, d (6.0)
13			4.01, br d (14.3) 4.03, br d (14.3)	7.22, d (6.0)	
14		3.31, d (16.5) 3.33, d (16.5)		1.46, s	
15	1.18, s	0.96, s	1.26, s	1.17, s	
16				1.04, d (7.2)	

^a Taken in CD₃OD, ^b Taken in CDCl₃.

Asperpene B (**2**): White powders; $[\alpha]_D^{25}$ –6 (c 0.1, MeOH); UV (MeOH) λ_{max} (log ϵ): 213 (3.14) nm, 215 (3.14) nm; ECD (MeOH) λ_{max} 295 (–0.06), 255 (+0.02), 229 (–0.08) nm; IR (KBr) ν_{max} (cm⁻¹): 3446, 2932, 2867, 1692, 1638, 1455, 1393, 1255, 1049. ¹H NMR data, Table 2; ¹³C NMR data, Table 3; HRESIMS m/z 273.1455 [M + Na]⁺ (calcd for C₁₅H₂₃O₃Na, 273.1461).

Asperpene C (**3**): White powders; $[\alpha]_D^{25}$ +5 (c 0.1, MeOH); UV (MeOH) λ_{max} (log ϵ): 202 (3.34) nm; IR (KBr) ν_{max} (cm⁻¹): 3415, 2959, 1708, 1456, 1184, 1122. ¹H NMR data, Table 2; ¹³C NMR data, Table 3; HRESIMS m/z 273.1457 [M + Na]⁺ (calcd for C₁₅H₂₂O₃Na, 273.1461).

12,13-Dedihydroversiol (**4**): Yellow oil; $[\alpha]_D^{25}$ –8 (c 0.1, MeOH); UV (MeOH) λ_{max} (log ϵ): 260 (3.46) nm, 234 (3.58) nm, 219 (3.66) nm; ECD (MeOH) λ_{max} 310 (+0.02), 261 (–0.31), 230 (+0.14) nm; IR (KBr) ν_{max} (cm⁻¹): 3445, 2930, 1723, 1655, 1605, 1454, 1385, 1266, 1108. ¹H NMR data, Table 2; ¹³C NMR data, Table 3; HRESIMS m/z 283.1297 [M + Na]⁺ (calcd for C₁₆H₂₀O₃Na, 283.1305).

Methyl 6-oxo-3, 6-dihydro-2H-pyran-4-carboxylate (**5**): Colorless oil; UV (MeOH) λ_{max} (log ϵ): 218 (3.45); IR (KBr) ν_{max} (cm⁻¹): 2927, 1726, 1641, 1441, 1260, 1219, 1084. ¹H NMR data, Table 2; ¹³C NMR data, Table 3; HRESIMS m/z 179.0316 [M + Na]⁺ (calcd for C₇H₈O₄Na, 179.0315).

Table 3. ^{13}C NMR data (125 MHz, δ in ppm) of 1–5.

Position	1 ^a	2 ^b	3 ^b	4 ^b	5 ^b
	δ_{C} , Type	δ_{C} , Type	δ_{C} , Type	δ_{C} , Type	δ_{C} , Type
1	39.8, CH ₂	36.7, CH ₂	38.9, CH ₂	66.8, CH	
2	47.0, CH	35.8, CH	36.7, CH	38.4, CH ₂	66.7, CH ₂
3	49.2, C	38.3, C	38.2, C	25.4, CH	23.7, CH ₂
4	26.6, CH ₂	30.0, CH ₂	30.4, CH ₂	138.2, CH	145.3, C
5	30.7, CH ₂	25.7, CH ₂	24.7, CH ₂	129.6, C	126.1, CH
6	37.2, CH	45.4, CH	46.6, CH	134.9, CH	163.6, C
7	133.9, C	132.0, C	139.5, C	124.9, CH	165.0, C
8	143.3, CH	145.1, CH	125.5, CH	85.9, C	53.1, CH ₃
9	40.8, CH	40.2, CH	38.8, CH	50.9, C	
10	44.5, CH ₂	42.2, CH ₂	44.3, CH ₂	40.8, CH	
11	39.0, C	42.9, C	48.3, C	198.8, C	
12	26.5, CH ₃	26.2, CH ₃	27.5, CH ₃	104.6, CH	
13	170.3, C	171.2, C	65.5, CH ₂	161.0, CH	
14	182.4, C	72.1, CH ₂	184.7, C	19.2, CH ₃	
15	27.8, CH ₃	26.8, C	26.3, CH ₃	13.5, CH ₃	
16				21.2, CH ₃	

^a Taken in CD₃OD, ^b Taken in CDCl₃.

X-ray Crystal Data for 1 and 6: Colorless crystals of **1** and **6** were obtained in the mixed solvent of MeOH and H₂O. Crystal data of **1** and **6** were obtained on a Bruker D8 QUEST diffractometer (Bruker) with graphite monochromated Cu K α radiation ($\lambda = 1.54178 \text{ \AA}$). Crystallographic data for **1** and **6** have been deposited with in the Cambridge Crystallographic Data Center as supplementary publication numbers CCDC 1875828 and 1875827. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Crystal data for **1**. Orthorhombic, C₁₅H₂₀O₄; space group P 21 21 21 with $a = 7.2684(6) \text{ \AA}$, $b = 9.6858(7) \text{ \AA}$, $c = 19.5962(15) \text{ \AA}$, $V = 1379.58(18) \text{ \AA}^3$, $Z = 4$, $D_{\text{calcd}} = 1.273 \text{ g/cm}^3$, $\mu = 0.747 \text{ mm}^{-1}$, and $F(000) = 568$. $T = 296(2) \text{ K}$. $R1 = 0.0583$ ($I > 2\sigma(I)$), $wR2 = 0.1409$ (all data), $S = 0.978$. Absolute structure parameter: 0.0 (4). The structures were solved using ShelXS. The structural solutions were found by direct methods and refined using the ShelXL package by least-squares minimization. The final structures were examined using the Addsym subroutine of PLATON to assure that no additional symmetry could be applied to the models. All non-hydrogen atoms were refined with anisotropic thermal factors.

Crystal data for **6**. Orthorhombic, C₁₆H₂₂O₃; space group P 21 21 21 with $a = 6.0879(2) \text{ \AA}$, $b = 9.1456(3) \text{ \AA}$, $c = 25.1933(9) \text{ \AA}$, $V = 1402.70(8) \text{ \AA}^3$, $Z = 4$, $D_{\text{calcd}} = 1.237 \text{ Mg/m}^3$, $\mu = 0.674 \text{ mm}^{-1}$, and $F(000) = 564$. $T = 296(2) \text{ K}$. $R1 = 0.0339$ ($I > 2\sigma(I)$), $wR2 = 0.0793$ (all data), $S = 1.060$. Absolute structure parameter: 0.08(12). The structures were solved using ShelXS. The structural solutions were found by direct methods and refined using the ShelXL package by least-squares minimization. The final structures were examined using the Addsym subroutine of PLATON to assure that no additional symmetry could be applied to the models. All non-hydrogen atoms were refined with anisotropic thermal factors.

4. Conclusions

In conclusion, five new compounds (**1–5**) and 10 known compounds (**6–15**) were isolated from the fermentation broth of *Aspergillus* sp. SCS-KFD66 which was isolated from a bivalve mollusk, *S.anguinolaria chinensis*, collected from Haikou Bay, China. The structures of the isolated compounds were unambiguously determined by spectroscopic data, single-crystal X-ray diffraction analysis, and comparison of the calculated and experimental ECD spectra. Compounds **7**, **8**, **12**, and **13** showed antibacterial activity against *Bacillus subtilis*, with MIC values of 4, 128, 128, and 128 $\mu\text{g/mL}$. Compounds **7**, **8**, **14**, and **15** exhibited antibacterial activity against *S.taphylococcus aureus*,

with MIC values of 16, 128, 128, and 2 µg/mL, while **15** also showed inhibitory activity against *L.isteria monocytogenes*, with MIC value of 128 µg/mL. Compounds **1**, **3**, **4**, **8**, **11**, and **15** showed a weak DPPH radical scavenging activity, with IC₅₀ values of 1.8, 0.6, 1.1, 0.6, 1.2, and 0.7 mM (ascorbic acid as positive control, IC₅₀ 0.04 mM).

Supplementary Materials: The following are available online in <http://www.mdpi.com/1660-3397/16/12/468/s1>, Figures S1–S39: HRESIMS, IR, and 2D NMR spectra of the new compounds **1–5**, the 18S rRNA gene sequence of *Aspergillus* sp. SCS-KFD66, and the quantum calculation details are supplied.

Author Contributions: C.A. contributed to fungal isolation and fermentation and compounds purification. F.K. was responsible for the structural elucidation, chemical computation, and preparation of the paper. Q.M. and L.Z. contributed to the bioassays. Q.X. identified the fungal strain. J.Y. collected the NMR data. H.D. revised the paper. Z.Y. and Y.Z. designed the work and revised the paper.

Funding: This work was supported by the Natural Science Foundation of Hainan Province (417256), Natural Science Foundation of China (41606088, 81741157), Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of Education, Hainan Normal University (HNSD201705), Financial Fund of the Ministry of Agriculture and Rural Affairs, P. R. of China (NFZX2018), and Central Public-Interest Scientific Institution Basal Research Fund for Chinese Academy of Tropical Agricultural Sciences (17CXTD-15, 1630052016008).

Acknowledgments: We wish to thank Junfeng Wang (CAS Key Laboratory of Tropical Marine Bio-resources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, China) for collection of ECD spectra.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Blunt, J.W.; Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.* **2018**, *35*, 8–53. [[CrossRef](#)] [[PubMed](#)]
2. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. *J. Nat. Prod.* **2016**, *79*, 629–661. [[CrossRef](#)] [[PubMed](#)]
3. Hamed, I.; Ozogul, F.; Ozogul, Y.; Regenstein, J.M. Marine bioactive compounds and their health benefits: A review. *Compr. Rev. Food Sci. Food Saf.* **2015**, *14*, 446–465. [[CrossRef](#)]
4. Ren, J.W.; Niu, S.B.; Li, L.; Geng, Z.F.; Liu, X.Z.; Che, Y.X. Identification of oxaphenalenone ketals from the ascomycete fungus *Neonectria* sp. *J. Nat. Prod.* **2015**, *78*, 1316–1321. [[CrossRef](#)] [[PubMed](#)]
5. Kong, F.D.; Ma, Q.Y.; Huang, S.Z.; Wang, P.; Wang, J.F.; Zhou, L.M.; Yuan, J.Z.; Dai, H.F.; Zhao, Y.X. Chrodriamans K–N and related meroterpenoids from the fungus *Penicillium* sp. SCS-KFD09 isolated from a marine worm, *Sipunculus nudus*. *J. Nat. Prod.* **2017**, *80*, 1039–1047. [[CrossRef](#)] [[PubMed](#)]
6. Kong, F.D.; Zhang, R.S.; Ma, Q.Y.; Xie, Q.Y.; Wang, P.; Chen, P.W.; Zhou, L.M.; Dai, H.F.; Luo, D.Q.; Zhao, Y.X. Chrodriamans O–S from the fungus *Penicillium* sp. SCS-KFD09 isolated from a marine worm, *Sipunculus nudus*. *Fitoterapia* **2017**, *122*, 1–6. [[CrossRef](#)] [[PubMed](#)]
7. Kong, F.D.; Huang, X.L.; Ma, Q.Y.; Xie, Q.Y.; Wang, P.; Chen, P.W.; Zhou, L.M.; Yuan, J.Z.; Dai, H.F.; Luo, D.Q.; et al. Helvolic acid derivatives with antibacterial activities against *Streptococcus agalactiae* from the marine-derived fungus *Aspergillus fumigatus* HNMF0047. *J. Nat. Prod.* **2018**, *81*, 1869–1876. [[CrossRef](#)] [[PubMed](#)]
8. Kong, F.D.; Zhou, L.M.; Ma, Q.Y.; Huang, S.Z.; Wang, P.; Dai, H.F.; Zhao, Y.X. Metabolites with Gram-negative bacteria quorum sensing inhibitory activity from the marine animal endogenic fungus *Penicillium* sp. SCS-KFD08. *Arch. Pharm. Res.* **2017**, *40*, 25–31. [[CrossRef](#)] [[PubMed](#)]
9. Qiu, L.M.; Wang, P.; Liao, G.; Zeng, Y.B.; Cai, C.H.; Kong, F.D.; Guo, Z.K.; Proksch, P.; Dai, H.F.; Mei, W.L. New eudesmane-type sesquiterpenoids from the mangrove-derived endophytic fungus *Penicillium* sp. *J. Nat. Prod.* **2018**, *16*, 108. [[CrossRef](#)] [[PubMed](#)]
10. Fujii, Y.; Asahara, M.; Ichinoe, M.; Nakajima, H. Fungal melanin inhibitor and related compounds from *Penicillium decumbens*. *Phytochemistry* **2002**, *60*, 703–708. [[CrossRef](#)]
11. Ballini, R.; Bosica, G. Synthesis of (E)-4-oxonon-2-enoic acid, a natural antibiotic produced by streptomyces olivaceus. *J. Nat. Prod.* **1998**, *61*, 673–674. [[CrossRef](#)] [[PubMed](#)]
12. Nagia, M.M.; El-Metwally, M.M.; Shaaban, M.; El-Zalabani, S.M.; Hanna, A.G. Four butyrolactones and diverse bioactive secondary metabolites from terrestrial *Aspergillus flavipes* MM2: Isolation and structure determination. *Org. Med. Chem. Lett.* **2012**, *2*, 9. [[CrossRef](#)] [[PubMed](#)]

13. Xie, P.; Zhang, Y.; Wang, X.; Wei, J.; Kang, W. Antithrombotic effect and mechanism of *Rubus* spp. Blackberry. *Food. Funct.* **2017**, *8*, 2000–2012. [[CrossRef](#)] [[PubMed](#)]
14. Hybelbauerova, S.; Sejbál, J.; Dracinsky, M.; Hahnova, A.; Koutek, B. Chemical constituents of *Stereum subtomentosum* and two other birch-associated basidiomycetes: An interspecies comparative study. *Chem. Biodivers.* **2008**, *5*, 743–750. [[CrossRef](#)] [[PubMed](#)]
15. Wang, Y.; Li, Z.L.; Liu, T.; Tian, L.; Pei, Y.H.; Hua, H.M. A new steroid with long cross-conjugation structure from the marine-derived fungus *Aspergillus aculeatus*. *Acta. Pharmacol. Sin.* **2014**, *49*, 68–71.
16. Kobata, K.; Wada, T.; Hayashi, Y.; Shibata, H. Volemolide, a novel norsterol from the fungus *Lactarius volemus*. *Biosci. Biotech. Bioch.* **1994**, *58*, 1542–1544. [[CrossRef](#)]
17. Li, Y.; Li, X.F.; Kim, D.S.; Choi, H.D.; Son, B.W. Indolyl alkaloid derivatives, N_b-Acetyltryptamine and oxaline from a marine-derived fungus. *Arch. Pharm. Res.* **2003**, *26*, 21–23. [[CrossRef](#)] [[PubMed](#)]
18. Feng, C.L.; Ma, Y.M. Isolation and Anti-phytopathogenic Activity of Secondary Metabolites from *Alternaria* sp. FL25, an Endophytic Fungus in *Ficus carica*. *Chin. J. Appl. Environ. Biol.* **2010**, *16*, 76–78. [[CrossRef](#)]
19. Sawadsitang, S.; Mongkoltharuk, W.; Suwannasai, N.; Sodngam, S. Antimalarial and cytotoxic constituents of *Xylaria* cf. *cubensis* PK108. *Nat. Prod. Res.* **2015**, *29*, 2033–2036. [[CrossRef](#)] [[PubMed](#)]
20. Yoshikawa, K.; Matsumoto, Y.; Hama, H.; Tanaka, M.; Zhai, H.F.; Fukuyama, Y.; Arihara, S.; Hashimoto, T. Russujaponols G-L, illudoid sesquiterpenes, and their neurite outgrowth promoting activity from the fruit body of *Russula japonica*. *Chem. Pharm. Bull.* **2009**, *57*, 311–314. [[CrossRef](#)] [[PubMed](#)]
21. Guo, J.J.; Dai, B.L.; Chen, N.P.; Jin, L.X.; Jiang, F.S.; Ding, Z.S.; Qian, C.D. The anti-*Staphylococcus aureus* activity of the phenanthrene fraction from fibrous roots of *Bletilla striata*. *BMC. Complem. Altern. Med.* **2016**, *16*, 491. [[CrossRef](#)] [[PubMed](#)]
22. Gil, M.I.; Tomas-Barberan, F.A.; Hess-Pierce, B.; Holcroft, D.M.; Kader, A.A. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. *J. Agric. Food. Chem.* **2000**, *48*, 4581–4589. [[CrossRef](#)] [[PubMed](#)]
23. Ellman, G.L.; Courtney, K.D.; Andres, V.J.; Feather-stone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* **1961**, *7*, 88–95. [[CrossRef](#)]
24. Jong-Anurakkun, N.; Bhandari, M.R.; Kawabata, J. α -glucosidase inhibitors from Devil tree (*Alstonia scholaris*). *Food. Chem.* **2007**, *103*, 1319–1323. [[CrossRef](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).